Presented by the Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer
SITC collaborated with the Cancer Drug Development Forum (CDDF) on the third European meeting that provided a platform for preclinical and clinical researchers in the field of immunotherapy. The concept was timely and necessary as agents had been licensed and arrived in clinical practice and many more similar drugs were expected to follow.
The goal of the conference was to provide a forum for discussion of early clinical drug development and address the unique challenges of drug development. ITOC is designed to provide a highly interactive platform. In so doing, the program attracted a multi-stakeholder attendance connecting preclinical and clinical scientists, clinicians, healthcare professionals, academia and other stakeholders who are involved in the development of novel anticancer agents. ITOC is renowned within its audience for the highly scientific character of its lectures.
SITC Board of Directors President, Dr. Howard L. Kaufman, served as Co-President of the conference, together with Dr. Alexander M.M. Eggermont and Dr. Volkmar Nüssler. SITC Board of Directors Vice President Dr. Lisa Butterfield is on the Scientific Committee for the program.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org